Kamada Ltd. (NASDAQ:KMDA – Get Rating) saw a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 5,400 shares, a drop of 60.6% from the April 30th total of 13,700 shares. Based on an average daily trading volume, of 20,300 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.0% of the shares of the company are sold short.
Institutional Trading of Kamada
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KMDA. Altshuler Shaham Ltd bought a new stake in shares of Kamada in the 1st quarter valued at approximately $1,645,000. Group One Trading L.P. raised its position in shares of Kamada by 103.7% during the first quarter. Group One Trading L.P. now owns 11,064 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 307,831 shares during the period. Phoenix Holdings Ltd. raised its position in Kamada by 12.4% during the third quarter. Phoenix Holdings Ltd. now owns 2,059,911 shares of the biotechnology company’s stock valued at $9,105,000 after buying an additional 227,819 shares during the period. Arete Wealth Advisors LLC acquired a new position in Kamada during the fourth quarter valued at $949,970,200,000. Finally, Millennium Management LLC purchased a new position in Kamada in the fourth quarter valued at about $314,000. Hedge funds and other institutional investors own 15.29% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on the stock. StockNews.com began coverage on shares of Kamada in a report on Tuesday. They issued a “buy” rating on the stock. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Kamada in a report on Thursday, March 16th.
Kamada Stock Down 1.6 %
Kamada (NASDAQ:KMDA – Get Rating) last issued its quarterly earnings results on Wednesday, March 15th. The biotechnology company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.04. Kamada had a positive return on equity of 8.17% and a negative net margin of 1.74%. The firm had revenue of $45.44 million during the quarter, compared to the consensus estimate of $44.64 million. As a group, research analysts expect that Kamada will post 0.12 EPS for the current fiscal year.
Kamada Company Profile
Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties.
- Get a free copy of the StockNews.com research report on Kamada (KMDA)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.